Jacob Johnson
Stock Analyst at Stephens & Co.
(2.91)
# 1,692
Out of 5,072 analysts
75
Total ratings
45.76%
Success rate
9.16%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $266.28 | -9.87% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.20 | -3.23% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $7.90 | -24.05% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $35.50 | +69.01% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $226.78 | +38.90% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $590.83 | +15.09% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $171.02 | -0.60% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $4.71 | +6.16% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $1.76 | +525.00% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $23.36 | +62.67% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $9.62 | +76.72% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.77 | +41.64% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $64.51 | +34.86% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $277.25 | +40.67% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $12.10 | +48.76% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.73 | +247.83% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $26.51 | +9.41% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $178.14 | +111.63% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $266.28
Upside: -9.87%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.20
Upside: -3.23%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $7.90
Upside: -24.05%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $35.50
Upside: +69.01%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $226.78
Upside: +38.90%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $590.83
Upside: +15.09%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $171.02
Upside: -0.60%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $4.71
Upside: +6.16%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.76
Upside: +525.00%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $23.36
Upside: +62.67%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $9.62
Upside: +76.72%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.77
Upside: +41.64%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $64.51
Upside: +34.86%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $277.25
Upside: +40.67%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $12.10
Upside: +48.76%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $1.73
Upside: +247.83%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $26.51
Upside: +9.41%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $178.14
Upside: +111.63%